Literature DB >> 19332037

Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience.

John H Krystal1, Alexander Neumeister.   

Abstract

Posttraumatic stress disorder (PTSD) is characterized mainly by symptoms of re-experiencing, avoidance and hyperarousal as a consequence of catastrophic and traumatic events that are distinguished from ordinary stressful life events. Although extensive research has already been done, the etiology of PTSD remains unclear. Research on the impact of trauma on neurobiological systems can be expected to inform the development of treatments that are directed specifically to symptoms of PTSD. During the past 25 years there has been a dramatic increase in the knowledge about noradrenergic and serotonergic mechanisms in stress response, PTSD and more recently in resilience and this knowledge has justified the use of antidepressants with monoaminergic mechanisms of action for patients with PTSD. Nevertheless, available treatments of PTSD are only to some extent effective and enhanced understanding of the neurobiology of PTSD may lead to the development of improved treatments for these patients. In the present review, we aim to close existing gaps between basic research in psychopathology, neurobiology and treatment development with the ultimate goal to translate basic research into clinically relevant findings which may directly benefit patients with PTSD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332037      PMCID: PMC2761677          DOI: 10.1016/j.brainres.2009.03.044

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  104 in total

1.  Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults.

Authors:  C R Brewin; B Andrews; J D Valentine
Journal:  J Consult Clin Psychol       Date:  2000-10

2.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

Authors:  M E Thase; A R Entsuah; R L Rudolph
Journal:  Br J Psychiatry       Date:  2001-03       Impact factor: 9.319

3.  A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors.

Authors:  K M Small; S L Forbes; F F Rahman; K M Bridges; S B Liggett
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

4.  Plasma neuropeptide-Y concentrations in humans exposed to military survival training.

Authors:  C A Morgan; S Wang; S M Southwick; A Rasmusson; G Hazlett; R L Hauger; D S Charney
Journal:  Biol Psychiatry       Date:  2000-05-15       Impact factor: 13.382

5.  Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats.

Authors:  M Rusnák; R Kvetnanský; J Jeloková; M Palkovits
Journal:  Brain Res       Date:  2001-04-27       Impact factor: 3.252

6.  Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression.

Authors:  M Y Zhu; V Klimek; G E Dilley; J W Haycock; C Stockmeier; J C Overholser; H Y Meltzer; G A Ordway
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

7.  Gender differences in susceptibility to posttraumatic stress disorder.

Authors:  M B Stein; J R Walker; D R Forde
Journal:  Behav Res Ther       Date:  2000-06

8.  The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task.

Authors:  R A Avery; J S Franowicz; C Studholme; C H van Dyck; A F Arnsten
Journal:  Neuropsychopharmacology       Date:  2000-09       Impact factor: 7.853

Review 9.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

Authors:  Andrea Cipriani; Toshiaki A Furukawa; Georgia Salanti; John R Geddes; Julian Pt Higgins; Rachel Churchill; Norio Watanabe; Atsuo Nakagawa; Ichiro M Omori; Hugh McGuire; Michele Tansella; Corrado Barbui
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

10.  Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD.

Authors:  A M Rasmusson; R L Hauger; C A Morgan; J D Bremner; D S Charney; S M Southwick
Journal:  Biol Psychiatry       Date:  2000-03-15       Impact factor: 13.382

View more
  86 in total

Review 1.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

2.  Protective factors for posttraumatic stress disorder symptoms in a prospective study of police officers.

Authors:  Chengmei Yuan; Zhen Wang; Sabra S Inslicht; Shannon E McCaslin; Thomas J Metzler; Clare Henn-Haase; Brigitte A Apfel; Huiqi Tong; Thomas C Neylan; Yiru Fang; Charles R Marmar
Journal:  Psychiatry Res       Date:  2010-11-23       Impact factor: 3.222

3.  Peritraumatic Behavior Questionnaire - Observer Rated: Validation of the objective version of a measure for combat-related peritraumatic stress.

Authors:  Agorastos Agorastos; Abigail C Angkaw; Heather E Johnson; Christian J Hansen; Camille V Cook; Dewleen G Baker
Journal:  World J Psychiatry       Date:  2016-06-22

Review 4.  Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder.

Authors:  Sonya B Norman; Ursula S Myers; Kendall C Wilkins; Abigail A Goldsmith; Veselina Hristova; Zian Huang; Kelly C McCullough; Shannon K Robinson
Journal:  Neuropharmacology       Date:  2011-05-13       Impact factor: 5.250

5.  Endocannabinoid signaling within the basolateral amygdala integrates multiple stress hormone effects on memory consolidation.

Authors:  Piray Atsak; Daniela Hauer; Patrizia Campolongo; Gustav Schelling; Raquel V Fornari; Benno Roozendaal
Journal:  Neuropsychopharmacology       Date:  2014-12-30       Impact factor: 7.853

Review 6.  Neurobiology of Resilience: Interface Between Mind and Body.

Authors:  Flurin Cathomas; James W Murrough; Eric J Nestler; Ming-Hu Han; Scott J Russo
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

Review 7.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

Review 8.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 9.  Post-traumatic Stress Disorder and Cardiovascular Disease.

Authors:  Matthew M Burg; Robert Soufer
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

Review 10.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.